Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3732394 in Healthy Participants

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3732394 in Healthy Participants

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Combinectin (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man
  • Acronyms FTIH
  • Sponsors ViiV Healthcare

Most Recent Events

  • 04 Oct 2021 Status changed from completed to discontinued. The study was terminated early (following completion of SAD Cohort 3; 80 mg) based on PK/PD modelling which demonstrated the medicine's intended target profile was not achievable.
  • 23 Aug 2021 Status changed from discontinued to completed.
  • 16 Feb 2021 Status changed to discontinued due to following completion of SAD Cohort 3; 80 mg based on PK/PDmodelling which demonstrated the medicine's intended target profile was not achievable.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top